1. Home
  2. SSTK vs GYRE Comparison

SSTK vs GYRE Comparison

Compare SSTK & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSTK
  • GYRE
  • Stock Information
  • Founded
  • SSTK 2003
  • GYRE 2002
  • Country
  • SSTK United States
  • GYRE United States
  • Employees
  • SSTK N/A
  • GYRE N/A
  • Industry
  • SSTK EDP Services
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSTK Technology
  • GYRE Health Care
  • Exchange
  • SSTK Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • SSTK 1.1B
  • GYRE 1.1B
  • IPO Year
  • SSTK 2012
  • GYRE N/A
  • Fundamental
  • Price
  • SSTK $29.79
  • GYRE $10.79
  • Analyst Decision
  • SSTK Buy
  • GYRE
  • Analyst Count
  • SSTK 4
  • GYRE 0
  • Target Price
  • SSTK $50.33
  • GYRE N/A
  • AVG Volume (30 Days)
  • SSTK 970.9K
  • GYRE 111.4K
  • Earning Date
  • SSTK 02-19-2025
  • GYRE 11-13-2024
  • Dividend Yield
  • SSTK 4.06%
  • GYRE N/A
  • EPS Growth
  • SSTK N/A
  • GYRE N/A
  • EPS
  • SSTK 1.01
  • GYRE N/A
  • Revenue
  • SSTK $902,175,000.00
  • GYRE $105,033,000.00
  • Revenue This Year
  • SSTK $9.28
  • GYRE $25.32
  • Revenue Next Year
  • SSTK $12.47
  • GYRE $12.95
  • P/E Ratio
  • SSTK $29.24
  • GYRE N/A
  • Revenue Growth
  • SSTK 3.09
  • GYRE N/A
  • 52 Week Low
  • SSTK $27.30
  • GYRE $8.26
  • 52 Week High
  • SSTK $54.41
  • GYRE $26.37
  • Technical
  • Relative Strength Index (RSI)
  • SSTK 43.84
  • GYRE 45.15
  • Support Level
  • SSTK $27.30
  • GYRE $10.41
  • Resistance Level
  • SSTK $32.20
  • GYRE $11.36
  • Average True Range (ATR)
  • SSTK 2.25
  • GYRE 0.66
  • MACD
  • SSTK -0.09
  • GYRE 0.04
  • Stochastic Oscillator
  • SSTK 15.70
  • GYRE 35.48

About SSTK Shutterstock Inc.

Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Share on Social Networks: